The notices it replaced
- Reissues: PAR-25-058 Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
- 2 steps back: PAR-21-122 Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
- 3 steps back: PAR-18-761 Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
- 4 steps back: PAR-15-071 Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Pharmacodynamics and In vivo Efficacy Studies for Small Molecules and Biologics/Biotechnology Products (R21/R33)
Who won it before
70 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $30,250,310 in first-year total cost, median $388,946.
Most frequent study sections
- Neurological Sciences and Disorders A Study Section[NSD-A]35
- Neurological Sciences and Disorders B Study Section[NSD-B]26
- Special Emphasis Panel[ZNS1 SRB-N (17)]2
- Neurological Sciences and Disorders C Study Section[NSD-C]1
- Special Emphasis Panel[ZNS1 SRB-M (03)]1
Most frequent institutions
- UNIVERSITY OF WASHINGTON4
- CINCINNATI CHILDRENS HOSP MED CTR3
- AUBURN UNIVERSITY AT AUBURN2
- BRIGHAM AND WOMEN'S HOSPITAL2
- EMORY UNIVERSITY2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | A novel gene therapy approach to reduce neurotoxicity in Parkinson's disease1R61NS138813-01A1 · under PAR-21-122 | BRUNDIN, LENA CECILIAMANFREDSSON, FREDRIC | VAN ANDEL RESEARCH INSTITUTE, MI | $1,009,212 | ZNS1 |
| 2025 | Optimization of New Drugs for the Treatment of Essential Tremor1R61NS138810-01A1 · under PAR-21-122 | HODGETTS, KEVIN | BRIGHAM AND WOMEN'S HOSPITAL, MA | $864,552 | NSD |
| 2025 | SapC-based Brain-targeting Delivery of Long-acting Enzymes for Neuronopathic Gaucher Disease Therapy1R61NS138554-01A1 · under PAR-21-122 | QI, XIAOYANGSUN, YING | CINCINNATI CHILDRENS HOSP MED CTR, OH | $803,958 | NSD |
| 2025 | Preclinical development of novel site blocking ASOs for the treatment of Rett syndrome1R61NS144485-01 · under PAR-21-122 | GOGLIOTTI, ROCCO GEORGE | LOYOLA UNIVERSITY CHICAGO, IL | $774,361 | ZNS1 |
| 2025 | Development of brain-penetrant, histone evicting anthracycline drugs for treatment of diffuse midline glioma1R61NS144359-01 · under PAR-21-122 | KOLDOBSKIY, MICHAEL ATSUKAMOTO, TAKASHI | JOHNS HOPKINS UNIVERSITY, MD | $773,607 | NSD |
| 2025 | Preclinical development of DMD exon 44 skipping using AAV.U7snRNA: a versatile tool that can help 6-12% of DMD patient1R61NS136653-01A1 · under PAR-21-122 | FLANIGAN, KEVIN M | RESEARCH INST NATIONWIDE CHILDREN'S HOSP, OH | $519,166 | NSD |
| 2025 | Development of an oligonucleotide therapeutic for Dravet syndrome1R61NS138832-01A1 · under PAR-21-122 | GORE, BRYAN BENTLEYLEVI, BOAZ PIRIEMICH, JOHN K | ALLEN INSTITUTE, WA | $391,903 | NSD |
| 2025 | Targeting the ABCA1 cholesterol transporter to correct pathophysiological myelin formation in hereditary neuropathies1R61NS136656-01A1 · under PAR-21-122 | NOTTERPEK, LUCIA | UNIVERSITY OF NEVADA RENO, NV | $352,073 | NSD |
| 2024 | Therapeutic Targeting of KCNQ3 in KCNQ3 Gain-of-Function Disorder1R61NS130226-01A1 · under PAR-21-122 | SANDS, TRISTAN T | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $432,288 | ZNS1 |
| 2024 | tRNA Gene Replacement Therapy for tRNA-Synthetase Related Charcot-Marie-Tooth Disorder1R61NS136651-01 · under PAR-21-122 | BURGESS, ROBERT W.HARPER, SCOTT Q | JACKSON LABORATORY, ME | $430,265 | NSD |
| 2024 | Gene Therapy for Xeroderma Pigmentosum - Cockayne Syndrome.1R61NS135019-01A1 · under PAR-21-122 | PACAK, CHRISTINA A. | UNIVERSITY OF MINNESOTA, MN | $428,724 | NSD |
| 2024 | Development of NAT8L inhibitors for the Treatment of Canavan Disease1R61NS136652-01 · under PAR-21-122 | SLUSHER, BARBARA STAUCHTSUKAMOTO, TAKASHI | JOHNS HOPKINS UNIVERSITY, MD | $396,324 | NSD |
| 2024 | Novel Biologics to ablate choroid plexus for the treatment of neonatal hydrocephalus1R61NS138647-01 · under PAR-21-122 | GOTO, JUNEMANGANO, FRANCESCO | CINCINNATI CHILDRENS HOSP MED CTR, OH | $394,544 | NSD |
| 2024 | Gene Therapy for Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD)1R61NS131704-01A1 · under PAR-21-122 | LEE, HING CHEONG HENRYROTENBERG, ALEXANDERSAHIN, MUSTAFA | BOSTON CHILDREN'S HOSPITAL, MA | $352,701 | NSD |
| 2024 | Evaluating the disease modifying properties of dimethyl fumarate (DMF) for the prevention and treatment of pharmacoresistant epilepsy1R61NS130134-01A1 · under PAR-21-122 | SHEKH-AHMAD, TAWFEEQWHITE, H STEVE | UNIVERSITY OF WASHINGTON, WA | $285,181 | NSD |
| 2023 | Small molecule inhibitors of TrkB Signaling1R61NS133213-01 · under PAR-21-122 | MCNAMARA, JAMES O. | DUKE UNIVERSITY, NC | $424,668 | NSD |
| 2023 | A Novel Neuroprotectant to Reduce Ischemic Injury1R61NS126700-01A1 · under PAR-21-122 | VAN LEYEN, KLAUS | MASSACHUSETTS GENERAL HOSPITAL, MA | $408,375 | NSD |
| 2023 | Investigational WNT-pathway modulators for the treatment and prevention of drug-resistant seizures1R61NS126626-01A1 · under PAR-21-122 | BARKER-HALISKI, MELISSA LEIGH | UNIVERSITY OF WASHINGTON, WA | $388,750 | NSD |
| 2023 | EP2 Antagonists for Ischemic Stroke1R61NS130199-01A1 · under PAR-21-122 | JIANG, JIANXIONGLIU, JIAWANG | UNIVERSITY OF TENNESSEE HEALTH SCI CTR, TN | $385,000 | NSD |
| 2023 | Development of the waixenicin A pharmacophore as a therapeutic intervention for neonatal hypoxic brain injury1R61NS124922-01A1 · under PAR-21-122 | FENG, ZHONG-PINGFLEIG, ANDREAHORGEN, F DAVIDHULL, KENNETH GREGORYMILLER, STEVEN PROMO, DANIELSUN, HONG-SHUO | BAYLOR UNIVERSITY, TX | $372,878 | NSD |
| 2023 | Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease1R61NS126618-01A1 · under PAR-21-122 | AMIN, RAJESH H | AUBURN UNIVERSITY AT AUBURN, AL | $361,569 | NSD |
| 2023 | VEGF-Mimetic Supramolecular Nanoparticles for Treating Spinocerebellar Ataxia Type 11R61NS127141-01A1 · under PAR-21-122 | OPAL, PUNEETSTUPP, SAMUEL I | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $361,272 | NSD |
| 2023 | Repurposing of R-etodolac for Alzheimer's disease and related disorders1R61NS126622-01A1 · under PAR-21-122 | KHALIL KADDOUMI, AMAL F | AUBURN UNIVERSITY AT AUBURN, AL | $308,662 | NSD |
| 2022 | Development of drugs that modify CNS innate immunity for the treatment of Multiple Sclerosis1R61NS114383-01A1 · under PAR-21-122 | HODGETTS, KEVINQUINTANA, FRANCISCO J. | BRIGHAM AND WOMEN'S HOSPITAL, MA | $434,860 | NSD |
| 2022 | Translational Studies to facilitate Rational Therapeutic Combinations of Letrozole for the Treatment of Glioblastoma1R61NS128232-01 · under PAR-21-122 | DESAI, PANKAJ B | UNIVERSITY OF CINCINNATI, OH | $389,244 | NSD |
| 2022 | Gene Therapy Clinical Candidate Development for Carbamoyl Phosphate Synthetase Deficiency1R61NS121348-01A1 · under PAR-18-761 | LIPSHUTZ, GERALD S | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $389,215 | NSD |
| 2022 | Targeting TRPC3 Channels for Epileptic Seizures1R61NS124923-01 · under PAR-18-761 | JIANG, JIANXIONGLI, WEI | UNIVERSITY OF TENNESSEE HEALTH SCI CTR, TN | $385,000 | NSD |
| 2022 | Targeting STAU1 for TDP-43 proteinopathies1R61NS124965-01A1 · under PAR-21-122 | PULST, STEFAN M.SCOLES, DANIEL R | UNIVERSITY OF UTAH, UT | $383,748 | NSD |
| 2022 | Nanoparticles with Two-Stage Delivery of Tetrodotoxin for Prolonged Duration Local Anesthesia1R61NS123196-01A1 · under PAR-21-122 | ZHAO, CHAO | UNIVERSITY OF ALABAMA IN TUSCALOOSA, AL | $322,128 | NSD |
| 2021 | Develop pan-specific antibody against mutant glycyl-tRNA synthetase for treating CMT2D1R61NS116211-01A1 · under PAR-18-761 | YANG, XIANG-LEI | SCRIPPS RESEARCH INSTITUTE, THE, CA | $431,350 | NSD |
| 2021 | Repurposing of KCa3.1 Inhibitor Senicapoc for Stroke: A Pre-clinical Study1R61NS123195-01 · under PAR-18-761 | WEINSTEIN, JONATHAN R | UNIVERSITY OF WASHINGTON, WA | $410,828 | NSD |
| 2021 | Development of prion protein-lowering divalent siRNA therapy for prion disease1R61NS119717-01 · under PAR-18-761 | MINIKEL, ERIC VALLABHVALLABH, SONIA MINIKEL | BROAD INSTITUTE, INC., MA | $399,878 | NSD |
| 2021 | Developing nonmuscle myosin II inhibitors for the treatment of glioblastoma1R61NS119714-01 · under PAR-18-761 | MILLER, COURTNEY AROSENFELD, STEVEN S | SCRIPPS FLORIDA, FL | $351,725 | NSD |
| 2021 | Characterization of Small Molecule Therapeutic Agents for a Lysosomal Leukodystrophy1R61NS118407-01A1 · under PAR-18-761 | MAEGAWA, GUSTAVO HENRIQUE BOFF | UNIVERSITY OF FLORIDA, FL | $152,765 | ZNS1 |
| 2020 | IGNITE: Development of novel cyclophilin B/PIKfyve inhibitors for treatment of Malignant Peripheral Nerve Sheath Tumors1R61NS111085-01A1 · under PAR-18-761 | BRAM, RICHARD JOLSON, STEVEN H | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $1,005,666 | NSD |
| 2020 | Optimization and Characterization of "MYC Degraders" for Pediatric Medulloblastoma1R61NS116191-01 · under PAR-18-761 | JACKSON, MICHAELWECHSLER-REYA, ROBERT J. | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $975,000 | NSD |
| 2020 | Therapeutic RNAi treatment for Myotonic Dystrophy1R61NS112447-01A1 · under PAR-18-761 | CHAMBERLAIN, JOEL R | UNIVERSITY OF WASHINGTON, WA | $820,746 | NSD |
| 2020 | Recombinant alpha-N-acetylglucosaminidase with improved mannose 6-phosphorylation for treatment of Sanfilippo B syndrome1R61NS111079-01A1 · under PAR-18-761 | DICKSON, PATRICIA IKORNFELD, STUART A | WASHINGTON UNIVERSITY, MO | $536,569 | ZNS1 |
| 2020 | Primary sensory neuron-targeted block of Cav3.2 for treatment of chronic neuropathic pain1R61NS116203-01 · under PAR-18-761 | HOGAN, QUINN HYU, HONGWEI | MEDICAL COLLEGE OF WISCONSIN, WI | $395,719 | NSD |
| 2020 | A Novel Pharmacologic Approach to Treat CMT1X1R61NS114355-01A1 · under PAR-18-761 | DOBROWSKY, RICK T | UNIVERSITY OF KANSAS LAWRENCE, KS | $387,165 | NSD |
| 2020 | Treatment of Lafora disease with an antibody-enzyme fusion1R61NS111081-01A1 · under PAR-18-761 | GENTRY, MATTHEW S.PAULY, JAMES R | UNIVERSITY OF KENTUCKY, KY | $382,500 | NSD |
| 2020 | Proteolipid protein suppression for Pelizaeus Merzbacher Disease1R61NS117774-01 · under PAR-18-761 | TESAR, PAUL JOSEPH | CASE WESTERN RESERVE UNIVERSITY, OH | $337,673 | NSD |
| 2020 | Novel Re-engineered L DOPA probiotic therapy for Parkinsons Disease1R61NS112441-01A1 · under PAR-18-761 | KANTHASAMY, ANUMANTHA GOUNDER | IOWA STATE UNIVERSITY, IA | $224,584 | ZNS1 |
| 2019 | Gene therapy for tuberous sclerosis1R61NS108232-01A1 · under PAR-18-761 | BREAKEFIELD, XANDRA OWENSMAGUIRE, CASEY ARAMESH, VIJAYA | MASSACHUSETTS GENERAL HOSPITAL, MA | $420,000 | NSD |
| 2019 | Treating seizures in TSC and FCD1R61NS111074-01 · under PAR-18-761 | BORDEY, ANGELIQUE | YALE UNIVERSITY, CT | $411,816 | NSD |
| 2019 | Development of ferroptosis inhibitors for Huntington Disease1R61NS109407-01A1 · under PAR-18-761 | STOCKWELL, BRENT R. | COLUMBIA UNIV NEW YORK MORNINGSIDE, NY | $400,327 | NSD |
| 2019 | Targeting complement 5a-mediated immunoregulation for neurofibroma therapy1R61NS112407-01 · under PAR-18-761 | RATNER, NANCYWU, JIANQIANG | CINCINNATI CHILDRENS HOSP MED CTR, OH | $397,500 | ZNS1 |
| 2019 | Optimizing oncolytic virus therapy for glioblastoma1R61NS112410-01 · under PAR-18-761 | KAUR, BALVEEN | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX | $385,000 | ZNS1 |
| 2019 | Preclinic dose and delivery regime optimization and long-term efficacy evaluation of ribitol treatment for FKRP related dystroglycanopathy1R61NS112545-01 · under PAR-18-761 | LU, QI L | CAROLINAS MEDICAL CENTER, NC | $378,291 | NSD |
| 2019 | Evaluation of Novel Dually Targeted Kinase Inhibitors for Therapy of Adult and Pediatric High-Grade Glioma1R61NS111058-01 · under PAR-18-761 | CHANDRA, JOYA | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $333,682 | NSD |
| 2019 | Targeted Drug Delivery for Spinal Cord Injury Using Retrograde Transport of a Nanoconjugate1R61NS112443-01 · under PAR-18-761 | MAO, GUANGZHAOSANKARI, ABDULGHANI | WAYNE STATE UNIVERSITY, MI | $256,234 | NSD |
| 2018 | Development and validation of small molecules to treat neurofibromatosis associated schwannoma1R21NS105941-01 · under PAR-15-071 | BANNISTER, THOMAS DKISSIL, JOSEPH | SCRIPPS FLORIDA, FL | $475,000 | NSD |
| 2018 | EP2 antagonists as novel anti-epileptogenic agents1R21NS101167-01A1 · under PAR-15-071 | GANESH, THOTA | EMORY UNIVERSITY, GA | $403,718 | NSD |
| 2018 | Use of CRISPR/Cas9 to treat Huntington disease1R21NS106120-01 · under PAR-15-071 | WARREN, STEPHEN T. | EMORY UNIVERSITY, GA | $390,000 | NSD |
| 2018 | DMF for intracerebral hemorrhage1R21NS104460-01 · under PAR-15-071 | ARONOWSKI, JAROSLAWSAVITZ, SEAN I | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX | $385,000 | NSD |
| 2018 | Reversal of preexisting neuropathic pain by spinal delivery of AIBP1R21NS104769-01A1 · under PAR-15-071 | MILLER, YURYYAKSH, TONY L. | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $380,298 | NSD |
| 2018 | 20-HETE Formation Inhibitors in Cardiac Arrest1R21NS107785-01 · under PAR-15-071 | MCDERMOTT, LEE APOLOYAC, SAMUEL M | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $369,304 | NSD |
| 2018 | Pharmacodynamics and in vivo efficacy of fumarate for mitochondrial disease in vivo1R21NS106719-01A1 · under PAR-15-071 | CORTOPASSI, GINO A | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $367,706 | NSD |
| 2018 | Exploring Antisense Oligonucleotides as a potential therapy for Autosomal Dominant Leukodystrophy1R21NS104384-01A1 · under PAR-15-071 | PADIATH, QUASAR S | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $353,208 | NSD |
| 2018 | Long Acting Local Analgesics: HSV-CA8 Biotherapeutics1R21NS105880-01 · under PAR-15-071 | LEVITT, ROY C. | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL | $329,297 | NSD |
| 2018 | Gene Therapy Knockdown and Replacement of GARS to Treat Dominant Inherited Peripheral Neuropathy1R21NS105116-01A1 · under PAR-15-071 | BURGESS, ROBERT W.HARPER, SCOTT Q | JACKSON LABORATORY, ME | $290,309 | NSD |
| 2017 | In vivo efficacy studies to support the development of DUX4-targeted RNAi therapy for FSHD1R21NS101166-01 · under PAR-15-071 | HARPER, SCOTT Q | RESEARCH INST NATIONWIDE CHILDREN'S HOSP, OH | $389,002 | NSD |
| 2017 | Neural Stem Cell Carriers for Glioblastoma Immunotherapy1R21NS101150-01 · under PAR-15-071 | BALYASNIKOVA, IRINA V | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $388,890 | NSD |
| 2017 | Complement inhibitors targeted to the ischemic brain for the treatment of stroke1R21NS097653-01A1 · under PAR-15-071 | TOMLINSON, STEPHEN | MEDICAL UNIVERSITY OF SOUTH CAROLINA, SC | $345,320 | NSD |
| 2016 | Global RNA Interference Therapy for Huntingtons Disease1R21NS095245-01A1 · under PAR-15-071 | MCBRIDE, JODI L. | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $437,500 | NSD |
| 2016 | Optimization of Compounds that Stabilize the SMN Protein for Treatment of SMA1R21NS095139-01 · under PAR-15-071 | ANDROPHY, ELLIOT J.HODGETTS, KEVINLORSON, CHRISTIAN L. | INDIANA UNIVERSITY INDIANAPOLIS, IN | $431,954 | NSD |
| 2016 | Efficacies and Pharmacodynamic Assays for LRRK2 Small-Molecule Inhibitors1R21NS097643-01 · under PAR-15-071 | WEST, ANDREW B | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $367,500 | NSD |
| 2016 | Red blood cell microparticles (RMPs) to reduce bleeding following hemorrhagic stroke1R21NS094896-01 · under PAR-15-071 | DAVE, KUNJAN R | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL | $307,000 | NSD |
| 2016 | Modified neural stem cells for glycosylation-independent treatment of MPS IIIB1R21NS096044-01 · under PAR-15-071 | IACOVINO, MICHELINA | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER, CA | $260,587 | NSD |
| 2016 | Development of Poly ICLC for neuroprotection against ischemic brain injury1R21NS094833-01A1 · under PAR-15-071 | STENZEL-POORE, MARY P | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $259,471 | NSD |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.